Full-Time

Senior Director

Therapeutic Research Technology

Posted on 8/26/2025

Lilly USA

Lilly USA

10,001+ employees

Global pharmaceutical company developing medicines

Compensation Overview

$154.5k - $226.6k/yr

+ Bonus

Remote in USA

Remote

Category
Biology & Biotech (4)
, , ,
Required Skills
Microsoft Azure
Agile
Python
Data Science
SQL
AWS
Databricks
Product Design
Google Cloud Platform
Requirements
  • Deep understanding of OMICS technologies and their application in drug discovery (scRNA-seq, bulk RNA-seq, spatial transcriptomics, proteomics, CRISPR, PerturbSeq)
  • Proven expertise in FAIR data principles and modern data governance frameworks
  • Sophisticated technical proficiency in SQL, Python, Databricks, and enterprise BI platforms
  • Experience navigating regulatory compliance requirements in pharmaceutical data management
  • Demonstrated success in developing and implementing science & technology strategies
  • Domain expertise in one or more focus areas: Neuroscience, Diabetes & Obesity, Oncology, or Immunology
  • Product management certifications (CSPO, CPM) or formal SDLC training
  • Cloud platform certifications (Azure, AWS, or GCP)
  • Previous experience in therapeutic area strategy or R&D leadership roles
  • Track record of successful digital transformation initiatives in pharmaceutical settings
  • Publications or presentations demonstrating thought leadership in computational biology or pharma IT
  • Exceptional ability to influence and align diverse team members from bench scientists to C-suite executives
  • Track record of leading ground-breaking change in complex pharmaceutical organizations
  • Outstanding communication skills with proven track record to translate technical complexity into business value
  • Experience building and mentoring high-performing, cross-functional teams
  • Strategic mentality combined with execution excellence and attention to detail
Responsibilities
  • Architect and implement comprehensive IT strategies across four therapeutic areas, ensuring seamless alignment with scientific priorities and business objectives
  • Partner with C-suite and therapeutic area leadership to champion ground-breaking digital initiatives that drive competitive advantage
  • Build forward-looking technology roadmaps that anticipate and exceed the evolving needs of modern drug discovery
  • Collaborate with scientific partners to define and deliver OMICS data capabilities supporting pre-clinical discovery, including scRNA-seq, spatial transcriptomics, proteomics, CRISPR, and PerturbSeq technologies
  • Champion the implementation of FAIR (Findable, Accessible, Interoperable, Reusable) data principles to improve research efficiency and reproducibility
  • Design and communicate product vision for therapeutic area-specific data platforms that accelerate the drug discovery pipeline
  • Establish scalable, cloud-native infrastructure supporting advanced OMICS data acquisition, processing, and analysis
  • Lead high-performing, multidisciplinary teams of bioinformaticians, data scientists, software engineers, and product designers
  • Apply Agile methodologies to manage sophisticated product development lifecycles spanning multiple therapeutic areas
  • Foster a culture of innovation and collaboration that breaks down silos between scientific and technical teams
  • Drive clear, critical communication that synthesizes diverse partner perspectives into unified action
  • Cultivate strategic relationships with industry-leading technology partners (DNAnexus, Broad Institute, BioTuring, Illumina) and academic institutions
  • Evaluate and integrate emerging technologies and data sources with ground-breaking potential for therapeutic research
  • Lead vendor selection and partnership negotiations to enhance value and innovation across the portfolio
  • Stay ahead of industry trends to find opportunities for competitive differentiation
  • Manage multi-million dollar budgets across direct and indirect IT investments for all four therapeutic areas
  • Drive operational excellence through process optimization and continuous improvement initiatives
  • Ensure timely delivery of high-impact projects while proactively leading risks and dependencies
  • Balance innovation investments with operational stability to increase ROI
Desired Qualifications
  • Advanced degree (Masters or higher) in life sciences, computational biology, or related field
  • 10+ years of progressive experience in biopharma, healthcare technology, or data-intensive life sciences organizations
  • 5+ years in technical product management, with demonstrated success in biopharma or healthcare sectors
  • 3+ years leading data science, AI, and informatics initiatives with measurable business impact

Lilly is a global pharmaceutical company that discovers, develops, and sells prescription medicines to improve health outcomes. It grows its portfolio through extensive research and development, then manufactures and distributes drugs worldwide to healthcare providers who prescribe them to patients. Lilly’s products span diabetes, cancer, immunology, pain management, and other serious conditions, including diabetes treatments tirzepatide and dulaglutide. The company emphasizes safety, efficacy, and ethical practices, and protects its products from counterfeiting while partnering with organizations such as Team USA. Its approach relies on rigorous R&D, strong manufacturing, and a global distribution network to bring medicines to patients. Lilly’s goal is to help people live better lives by delivering reliable medical solutions through a global, ethical, and quality-focused operation.

Company Size

10,001+

Company Stage

IPO

Headquarters

Indianapolis, Indiana

Founded

1876

Simplify Jobs

Simplify's Take

What believers are saying

  • Medicare's GLP-1 Bridge can broaden access to Mounjaro and Zepbound.
  • CVS restored Zepbound coverage and added Foundayo across major formularies.
  • Lilly can redeploy capital from Germany toward U.S. manufacturing expansion.

What critics are saying

  • Medicare's bridge program compresses pricing and shifts volume from premium channels.
  • CVS can re-prefer Wegovy or exclude obesity drugs entirely on sponsor opt-outs.
  • Lilly's tirzepatide concentration makes any safety, supply, or pricing shock severe.

What makes Lilly USA unique

  • Lilly dominates diabetes and obesity with Mounjaro and Zepbound, driving 56% revenue.
  • The company pairs blockbuster commercialization with deep R&D and global manufacturing scale.
  • Recent acquisitions add vaccines and non-viral genetic medicine platforms beyond GLP-1s.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Lilly USA who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Flexible Work Hours

Wellness Program

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-5%

2 year growth

-5%
The Lebanon Reporter
May 7th, 2026
Lilly invests additional $4.5B in LEAP district, opens first genetic medicine facility

Eli Lilly has announced an additional $4.5 billion investment in its Lebanon, Indiana facilities, bringing its total investment in the LEAP Innovation and Research district to $21 billion. The company opened its first Advanced Therapies site on Wednesday, marking the first operational facility in the 9,000-acre LEAP district. The new funding will support Lilly's Advanced Therapies laboratory and an active pharmaceutical ingredient facility expected to open in 2027. The Advanced Therapies site is Lilly's first dedicated genetic medicine manufacturing facility, focusing on molecular-level research for diseases including Alzheimer's, Parkinson's and ALS. Lilly is developing three facilities across 800 acres in LEAP, including a Medicine Foundry. The Advanced Therapies facility aims to accelerate delivery of breakthrough genetic medicines to patients.

AI Software Services
May 5th, 2026
Unlocking AI innovation in finance medicine and music.

Unlocking AI innovation in finance medicine and music. Published on May 05, 2026 GENETIC MEDICINE REVOLUTION: AI AND BIOTECH JOIN FORCES. In a groundbreaking partnership, Lilly and AI-driven Profluent Bio are teaming up in a deal worth up to $2.25 billion to develop advanced DNA editing tools. Their goal? To create precise treatments for genetic conditions that currently lack effective solutions, using innovative AI models to design enzymes that can target multiple mutations in the genome. This collaboration aims to unlock the "holy grail" of genetic medicine through kilobase-scale DNA editing. This matters because it could transform how AI Software Services treat genetic diseases, offering hope to millions who suffer from conditions deemed untreatable. The tools being developed are likely to be accessible, lowering barriers to entry in a field that has traditionally been expensive and exclusive. Imagine a startup that provides a platform for creators and developers to access these AI-driven genetic editing tools, enabling them to innovate and create personalized therapies. This could attract investors eager to support the next wave of medical breakthroughs!

The Economic Times
May 4th, 2026
French fines over anti-obesity adverts for Novo Nordisk, Eli Lilly.

French fines over anti-obesity adverts for Novo Nordisk, Eli Lilly. The ANSM fined Novo Nordisk 783,838 euros regarding adverts for Wegovy and also fined Lilly France 108,766 euros for a campaign promoting its anti-obesity drug Mounjaro, seeing the adverts as "likely to constitute indirect promotion of medicines subject to mandatory medical prescription." * Updated On May 4, 2026 at 05:54 PM IST Paris: France's medicine safety agency ANSM said Monday it had imposed fines on pharmaceutical firms Novo Nordisk and Eli Lilly over their advertising campaigns on obesity. The agency fined on Novo Nordisk France 1.78 million euros ($2.08 million) - a million relating to adverts promoting its Saxenda drug and 783,838 euros regarding adverts for Wegovy weight management medication for treating obesity. The ANSM also fined Lilly France 108,766 euros for a campaign promoting its anti-obesity drug Mounjaro, seeing the adverts as "likely to constitute indirect promotion of medicines subject to mandatory medical prescription." French laws prohibit any advertising to the general public of the treatments. The national medicines regulator said that the fines aimed to "prevent any communication likely to promote the use of drug treatment as the principal response to obesity, to encourage the public to request this treatment from a healthcare professional or seek to obtain it themselves." Event. * Fri, 24 Jul 2026 * Le Meridien, Hyderabad The ANSM said the advertising campaigns were "likely to mislead the public in a context marked by extensive media coverage" as well as what it termed growing inappropriate use of medications which activate certain hormones in order notably to reduce appetite,and aid weight loss. In a statement to AFP, Novo Nordisk France said it "strongly contests" the ANSM's finding, adding it is "exploring all possible appeal avenues against this decision". Lilly France said it noted ANSM's decision, while stating it believes its awareness campaign entitled "Obesity is a sick person's problem" from a year ago was "in line with the framework applicable to communications relating to human health". According to a French study published in 2024, around 18 percent of the French population - equivalent to some ten million people - are obese.

NBC News
Apr 14th, 2026
FDA requests more safety data from Lilly on weight loss pill Foundayo

The FDA is requesting additional safety data from Eli Lilly for its weight loss pill Foundayo, including information on potential heart and liver problems, according to the approval letter published Tuesday. The agency wants more data on risks including heart attacks, strokes, drug-induced liver injuries and delayed stomach emptying. Foundayo, approved this month under a fast-track pilot programme, is the second oral GLP-1 to reach market after Novo Nordisk's Wegovy pill. The FDA is also asking Lilly to collect thyroid cancer risk data for at least 15 years. The requests are considered routine for newly approved drugs, particularly for orforglipron, Foundayo's active ingredient, which has less safety data than older GLP-1s. Lilly must also establish registries tracking children with obesity and pregnancy outcomes.

PR Newswire
Apr 14th, 2026
Vasa Therapeutics partners with Lilly TuneLab to accelerate AI-driven CAMKII inhibitor development

Vasa Therapeutics, a clinical-stage biopharmaceutical company, has partnered with Eli Lilly to use Lilly TuneLab, an AI-enabled drug discovery platform that provides access to models trained on Lilly's proprietary research data. Vasa will use the platform to accelerate development of its CAMKII delta inhibitor, which is planned for Phase 1 clinical trials in 2027. The company's VS-041 is currently in a proof-of-mechanism trial for heart failure, whilst VS-214 is on track for first-in-human trials in 2026. The platform uses federated learning, allowing companies to access Lilly's AI models whilst maintaining data privacy. Vasa will contribute its own experimental datasets to support the platform's improvement. The company focuses on developing therapies for cardiovascular, neuromuscular and age-related disorders.

INACTIVE